Market Overview

UPDATE: Loewen Ondaatje McCutcheon Downgrades BioMimetic Therapeutics to Hold, Reiterates $7.50 PT

Related BMTI
UPDATE: Wedbush Terminates Coverage on BioMimetic Therapeutics on Acquisition by Wright Medical
Loewen Ondaatje McCutcheon Reiterates Buy Rating, $7.50 PT on BioMimetic Therapeutics

In a report published Wednesday, Loewen Ondaatje McCutcheon downgraded its rating on BioMimetic Therapeutics (NASDAQ: BMTI) from Buy to Hold, but reiterated its $7.50 price target.

Loewen Ondaatje McCutcheon noted, “With BMTI trading within proximity of our 12-month price target of $7.50 per share, we have downgraded the shares to Hold (from Buy), reflecting a more balanced risk/reward profile.”

BioMimetic Therapeutics closed on Tuesday at $6.94.

Posted-In: Loewen Ondaatje McCutcheonAnalyst Color Downgrades Analyst Ratings

 

Most Popular

Related Articles (BMTI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free